Basilea Pharmaceutica AG
BPMUF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -2.56 | -0.17 | 1.08 |
| FCF Yield | 12.52% | 3.15% | 0.66% | -7.53% |
| EV / EBITDA | 8.60 | 20.98 | 30.97 | 168.98 |
| Quality | ||||
| ROIC | 36.76% | 13.40% | 10.04% | 0.61% |
| Gross Margin | 81.45% | 83.00% | 83.35% | 83.75% |
| Cash Conversion Ratio | 0.96 | 1.36 | 0.58 | 4.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.17% | 2.10% | 5.00% | 3.30% |
| Free Cash Flow Growth | 449.32% | 252.01% | 111.41% | 41.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.14 | 2.96 | 4.72 | 46.39 |
| Interest Coverage | 14.08 | 1.71 | 1.88 | 0.15 |
| Efficiency | ||||
| Inventory Turnover | 1.22 | 1.01 | 1.01 | 1.06 |
| Cash Conversion Cycle | 288.90 | 344.70 | 496.53 | 245.95 |